Diabetes and Endocrinology - Global Cardiology Academy

1-16 of 26

Understanding Residual Cardiovascular Risk in CKD and T2D
Understanding Residual Cardiovascular Risk in CKD and T2D
Diabetes Discourse
Understanding Residual Cardiovascular Risk in CKD and T2D
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
Supporting Whole-Body Health Through the Gut
Supporting Whole-Body Health Through the Gut
NutritionEdge
Supporting Whole-Body Health Through the Gut
Shelina Ramnarine, PhD; Terri DeNeui, DNP, APRN, ACNP-BC
- Shelina Ramnarine, PhD
- Terri DeNeui, DNP, APRN, ACNP-BC
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart Matters
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP; Anu Lala, MD
- Brian P. McDonough, MD, FAAFP
- Anu Lala, MD
- Martha Gulati, MD, MS, FACC, FAHA
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
On the Frontlines of Familial Chylomicronemia Syndrome
Cardiometabolic Considerations in Familial Chylomicronemia Syndrome
Steve Jackson, PharmD; Robert H. Eckel, MD, FAHA, FACC, FNLA
- Steve Jackson, PharmD
- Robert H. Eckel, MD, FAHA, FACC, FNLA
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Heart Matters
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steve Jackson, PharmD; Robert J. Mentz, MD, FHFSA, FACC
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
Making UACR a Routine Part of Diabetes Care
Making UACR a Routine Part of Diabetes Care
Heart Matters
Making UACR a Routine Part of Diabetes Care
Steve Jackson, PharmD; Robert J. Mentz, MD, FHFSA, FACC
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Richard E. Pratley, MD
- Richard E. Pratley, MD
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
prof. Hiddo Heerspink; Peter Rossing, MD, DMSc
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Rajiv Agarwal, MBBS, MD, FASN, BRCU; Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
Diabetes and Endocrinology
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
Femke Rutters, PhD
- Femke Rutters, PhD
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Heart Matters
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Amy Mottl, MD, MPH; Prof. Christoph Wanner
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits

Prev
1
2
Next

1/2